The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
AMP‐activated protein kinase: a potential player in Alzheimer’s disease
Abstract
J. Neurochem. (2011) 118, 460–474. AMP‐activated protein kinase (AMPK) stimulates energy production via glucose and lipid metabolism, whereas it inhibits energy consuming functions, such as protein and cholesterol synthesis. Increased cytoplasmic AMP and Ca 2+ levels are the major activators of neuronal AMPK signaling. Interestingly, Alzheimer’s disease (AD) is associated with several abnormalities in neuronal energy metabolism, for example, decline in glucose uptake, mitochondrial dysfunctions and defects in cholesterol metabolism, and in addition, with problems in maintaining Ca 2+ homeostasis. Epidemiological studies have also revealed that many metabolic and cardiovascular diseases are risk factors for cognitive impairment and sporadic AD. Emerging studies indicate that AMPK signaling can regulate tau protein phosphorylation and amyloidogenesis, the major hallmarks of AD. AMPK is also a potent activator of autophagic degradation which seems to be suppressed in AD. All these observations imply that AMPK is involved in the pathogenesis of AD. However, the responses of AMPK activation are dependent on stimulation and the extent of activating stress. Evidently, AMPK signaling can repress and delay the appearance of AD pathology but later on, with increasing neuronal stress, it can trigger detrimental effects that augment AD pathogenesis. We will outline the potential role of AMPK function in respect to various aspects affecting AD pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 1×
“Recently, it was demonstrated that AMPK can directly activate ULK1 (unc-51-like kinase), the mammalian autophagy-initiating kinase (Lee et al. 2010b; Kim et al. 2011).”
BackgroundAutophagy in the Pathogenesis of Disease
Levine, B., & Kroemer, G. (2008) · Cell · doi:10.1016/j.cell.2007.12.018 · Cited by 7,069
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300 · cited 1×
“AMPK can regulate inflammation via (i) activating SIRT1, which inhibits NF-jB signaling (Yeung et al. 2004; Canto et al. 2009), (ii) stimulating FOXO proteins, for example, FOXO3a and FOXO4, which inhibit NF-jB signaling and prevent inflammation (Lin et al. 2004; Greer et al. 2007; Zhou et al.…”
BackgroundModulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
Hawley, S. A., Pan, D. A., Mustard, K. J., Ross, L., Bain, J., Edelman, A. M., Frenguelli, B. G., & Hardie, D. G. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.009 · Cited by 1,589 · cited 10×
“Ca2+ is a potent activator of AMPK via the activation of CaMKKb (Hawley et al. 2005; Woods et al. 2005).”
BackgroundInfluentialLee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212
Ribosomal Protein S6 Kinase 1 Signaling Regulates Mammalian Life Span
Selman, C., Tullet, J. M. A., Wieser, D., Irvine, E., Lingard, S. J., Choudhury, A. I., Claret, M., Al-Qassab, H., Carmignac, D., Ramadani, F., et al. (2009) · Science · doi:10.1126/science.1177221 · Cited by 1,120 · cited 1×
“Emerging studies indicate that AMPK signaling can regulate lifespan, probably by improving general health (Curtis et al. 2006; Selman et al. 2009; Mair et al. 2011).”
BackgroundSpilman, P., Podlutskaya, N., Hart, M. J., Debnath, J., Gorostiza, O., Bredesen, D., Richardson, A., Strong, R., & Galvan, V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009979 · Cited by 1,033 · cited 2×
“Several studies have indicated that autophagy inducers, either AMPK activators or mTOR inhibitors, have beneficial effects on the pathogenesis in AD transgenic mice (Spilman et al. 2010; Vingtdeux et al. 2010; Yang et al. 2011).”
BackgroundMacroautophagy—a novel β-amyloid peptide-generating pathway activated in Alzheimer's disease
Yu, W. H., Cuervo, A. M., Kumar, A., Peterhoff, C. M., Schmidt, S. D., Lee, J.-H., Mohan, P. S., Mercken, M., Farmery, M. R., Tjernberg, L. O., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505082 · Cited by 967 · cited 1×
“Moreover, they were enriched in APP and b-cleaved APP, thus creating a major pool of intraneuronal amyloid-b (Yu et al. 2005).”
Background
Cited by
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Chen, Z., & Zhong, C. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.004 · Cited by 673
Estrogen: A master regulator of bioenergetic systems in the brain and body
Rettberg, J. R., Yao, J., & Brinton, R. D. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.08.001 · Cited by 534
AMP-Activated Protein Kinase: A Target for Drugs both Ancient and Modern
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.08.019 · Cited by 372
Metformin treatment prevents amyloid plaque deposition and memory impairment in APP/PS1 mice
Ou, Z., Kong, X., Sun, X., He, X., Zhang, L., Gong, Z., Huang, J., Xu, B., Long, D., Li, J., et al. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.12.009 · Cited by 368
Mairet-Coello, G., Courchet, J., Pieraut, S., Courchet, V., Maximov, A., & Polleux, F. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.003 · Cited by 351
Koenig, A. M., Mechanic-Hamilton, D., Xie, S. X., Combs, M. F., Cappola, A. R., Xie, L., Detre, J. A., Wolk, D. A., & Arnold, S. E. (2017) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000202 · Cited by 350
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Querfurth, H., & Lee, H.-K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00428-5 · Cited by 288
An AMPK–caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
Zhao, P., Sun, X., Chaggan, C., Liao, Z., in Wong, K., He, F., Singh, S., Loomba, R., Karin, M., Witztum, J. L., et al. (2020) · Science · doi:10.1126/science.aay0542 · Cited by 307
Early glycolytic reprogramming controls microglial inflammatory activation
Cheng, J., Zhang, R., Xu, Z., Ke, Y., Sun, R., Yang, H., Zhang, X., Zhen, X., & Zheng, L.-T. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02187-y · Cited by 295
Role of RAGE in Alzheimer’s Disease
Cai, Z., Liu, N., Wang, C., Qin, B., Zhou, Y., Xiao, M., Chang, L., Yan, L.-J., & Zhao, B. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0233-3 · Cited by 285
Ashabi, G., Khalaj, L., Khodagholi, F., Goudarzvand, M., & Sarkaki, A. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-014-9632-2 · Cited by 256
Ma, T., Chen, Y., Vingtdeux, V., Zhao, H., Viollet, B., Marambaud, P., & Klann, E. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1694-14.2014 · Cited by 191
“Whether inhibition of AMPK activity would be either beneficial or detrimental in AD is a subject under debate (Salminen et al., 2011).”
BackgroundActivation of mTOR: a culprit of Alzheimer’s disease?
Cai, Z., Zhou, Y., Xiao, M., Yan, L.-J., & He, W. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s75717 · Cited by 161
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Roy, N., Hutfles, L., Burns, J. M., Michaelis, E. K., Yan, S., Cardoso, S. M., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt247 · Cited by 133
Liu, D., Tang, H., Li, X.-Y., Deng, M.-F., Wei, N., Wang, X., Zhou, Y.-F., Wang, D.-Q., Fu, P., Wang, J.-Z., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.018 · Cited by 127
Decoding microglial immunometabolism: a new frontier in Alzheimer's disease research
Jung, E. S., Choi, H., & Mook-Jung, I. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00825-0 · Cited by 124
Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development
Mueed, Z., Tandon, P., Maurya, S. K., Deval, R., Kamal, M. A., & Poddar, N. K. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01017 · Cited by 111
Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice
Chen, Y., Zhao, S., Fan, Z., Li, Z., Zhu, Y., Shen, T., Li, K., Yan, Y., Tian, J., Liu, Z., et al. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00761-9 · Cited by 111
Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer’s model mice
Zimmermann, H. R., Yang, W., Kasica, N. P., Zhou, X., Wang, X., Beckelman, B. C., Lee, J., Furdui, C. M., Keene, C. D., & Ma, T. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133982 · Cited by 86
“Multiple studies indicate a role of AMPK in AD-associated Aβ and tau pathology (5, 6, 53, 54).”
BackgroundMetformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs
Chung, M.-M., Nicol, C. J., Cheng, Y.-C., Lin, K.-H., Chen, Y.-L., Pei, D., Lin, C.-H., Shih, Y.-N., Yen, C.-H., Chen, S.-J., et al. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.01.017 · Cited by 66
CHANG, F., ZHANG, L.-H., XU, W.-P., JING, P., & ZHAN, P.-Y. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2013 · Cited by 59
Shah, S. Z. A., Zhao, D., Hussain, T., & Yang, L. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.09.004 · Cited by 55
Liu, Z., Zhang, Y., Liu, J., & Yin, F. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0875-9 · Cited by 21
“Mounting evidence demonstrates that leptin can also enhance the activation of AMPK pathways (Salminen et al. 2011), and activation of leptin signaling triggers the JAK/ STAT pathway to induce the changes of gene transcription (Jiang et al.”
BackgroundArsenic and Tau Phosphorylation: A Mechanistic Review
Ariafar, S., Makhdoomi, S., & Mohammadi, M. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03634-y · Cited by 13
Metadata
- Authors
- Salminen, A., Kaarniranta, K., Haapasalo, A., Soininen, H., & Hiltunen, M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-06-24
- Volume
- 118
- Issue
- 4
- Pages
- 460-474
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1601336661
- Cited by
- 222
- References
- 36
- FWCI
- 9.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.